WCM INVESTMENT MANAGEMENT, LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 122 filers reported holding BRIDGEBIO PHARMA INC in Q2 2020. The put-call ratio across all filers is 0.03 and the average weighting 0.7%.

Quarter-by-quarter ownership
WCM INVESTMENT MANAGEMENT, LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$7,501,922
+56.5%
284,487
+2.1%
0.02%
+57.1%
Q2 2023$4,792,849
-22.4%
278,654
-25.2%
0.01%
-30.0%
Q1 2023$6,177,509
+120.4%
372,588
+1.3%
0.02%
+122.2%
Q4 2022$2,802,567
-26.2%
367,791
-1.2%
0.01%
-35.7%
Q3 2022$3,799,000
+25.3%
372,432
+8.6%
0.01%
+27.3%
Q2 2022$3,033,000
-12.8%
343,069
+0.1%
0.01%
+10.0%
Q1 2022$3,480,000
+65.2%
342,857
+171.5%
0.01%
+100.0%
Q4 2021$2,106,000
-31.4%
126,270
+92.8%
0.01%
-28.6%
Q3 2021$3,070,000
-22.6%
65,504
+0.7%
0.01%
-30.0%
Q2 2021$3,964,000
-39.0%
65,022
-38.3%
0.01%
-44.4%
Q1 2021$6,494,000
-35.6%
105,428
-25.7%
0.02%
-33.3%
Q4 2020$10,087,000
+154.1%
141,849
+34.1%
0.03%
+92.9%
Q3 2020$3,969,000
+22.6%
105,796
+6.6%
0.01%
+16.7%
Q2 2020$3,237,000
+68.6%
99,273
+49.9%
0.01%
+9.1%
Q1 2020$1,920,00066,2230.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2020
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders